From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications

From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications

Navarese EP, Kołodziejczak M, Dimitroulis D, Wolff G, Busch HL, Devito F, Sionis A, Ciccone MM.

Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):44-53. doi: 10.1093/ehjcvp/pvv045. Epub 2015 Nov 29.

Abstract
Statins are recommended as first-line therapy for patients with hypercholesterolaemia. A sizable proportion of patients, however, does not reach therapeutic goals, is statin intolerant, or, despite optimal statin therapy, is at high risk of ischaemic events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in lipid metabolism and several comorbidities. Monoclonal antibodies targeting PCSK9 are a new lipid-lowering approach with the potential to improve clinical outcomes in patients with dyslipidaemia. In this review, we discuss current experimental and clinical evidence of the role of PCSK9 and its inhibition on lipid metabolism and several pathologic conditions with a focus on clinical outcomes. A state-of-the-art analysis of current clinical evidence and future directions on PCSK9 and its inhibition is provided.

KEYWORDS:
Clinical perspectives; PCSK9 inhibitors; Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Advertisements